Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb 9;9(5):1210-1219.
doi: 10.1016/j.ekir.2024.02.007. eCollection 2024 May.

Aortic Dilatation in Children and Young People With ADPKD

Affiliations

Aortic Dilatation in Children and Young People With ADPKD

Alexandra Savis et al. Kidney Int Rep. .

Abstract

Introduction: Aortic root dilatation is a reported cardiovascular sequela seen in children and young people (CYP) with chronic kidney disease (CKD) but has yet to be described in those with autosomal dominant polycystic kidney disease (ADPKD).

Methods: Single center, cross-sectional study in a dedicated ADPKD clinic. Echocardiograms were evaluated for the presence of dilatation (defined by a z-score ≥2 [≥99th percentile] SDs from the mean) at 4 standardized locations, namely the aortic valve annulus, sinuses of Valsalva (SoV), sinotubular junction (STJ), and the ascending aorta. Measurements were compared with a control group to assess prevalence, severity, and determinants of aortic dilatation.

Results: Ninety-seven children, median age (interquartile range) of 9.3 (6.1, 13.6) years were compared with 19 controls without ADPKD or other CKD. The prevalence of dilatation ranged from 5.2% to 17% in ADPKD, depending on anatomical location with no aortic dilatation identified in the control group. In multivariable regression, aortic root dilatation was significantly associated with cyst burden at the aortic valve annulus and SoV (β = 0.42 and β = 0.39, both P < 0.001), with age at SoV (β = -0.26, P = 0.02), systolic blood pressure (SBP) z-score at SoV (β = -0.20, P = 0.04) and left ventricular mass index (LVMI) at SoV and STJ (β = 0.24, P = 0.02 and β = 0.25, P = 0.03, respectively) following adjustment for age, sex (male or female), body mass index (BMI) z-score, estimated glomerular filtration rate (eGFR), SBP z-score, and LVMI.

Conclusion: Our data suggests increased prevalence of aortic root and ascending aortic dilatation in CYP with ADPKD compared with controls. Further studies are needed to understand the pathogenesis and its contribution to the high cardiovascular morbidity in ADPKD.

Keywords: ADPKD; aortic root; children; dilatation; echocardiography.

PubMed Disclaimer

Figures

None
Graphical abstract
Figure 1
Figure 1
Parasternal long-axis echocardiographic image showing the aortic measurements. Ao, aorta; LA, left atrium; LV, left ventricle; MV, mitral valve; RV, right ventricle; SoV, sinuses of Valsalva; STJ, sinotubular junction The aortic root and ascending is measured at 4 standardized places, inner-edge to inner-edge technique in end-systole as indicated by the arrows: the aortic valve annulus (1); SoV (2), STJ (3) and the ascending aorta at its widest diameter, at least 2cm above the STJ (4).
Figure 2
Figure 2
Distribution of aortic z-scores in 97 children and young people with ADPKD and healthy controls without ADPKD. ADPKD, autosomal dominant polycystic kidney disease. Aortic dilatation was defined as z-score ≥2 (≥99th percentile) using the Lopez Pediatric Heart Network regression equations.
Figure 3
Figure 3
Aortic diameters in mm and as z-scores in 97 children and young people with ADPKD stratified by cyst burden and compared with healthy controls. ADPKD, autosomal dominant polycystic kidney disease; AoV, aortic valve annulus; AsAo, ascending aorta; SBP, systolic blood pressure; SoV, sinuses of Valsalva; STJ, sinotubular junction Data shown as marginal means after adjustment for age, sex (male or female), and SBP z-score. Error bars represent 95% confidence interval. Panel A: aortic diameters in mm; Panel B aortic diameter z-scores. P-values refer to difference between groups assessed by analysis of variance.

References

    1. Torres V.E., Harris P.C., Pirson Y. Autosomal dominant polycystic kidney disease. Lancet. 2007;369:1287–1301. doi: 10.1016/S0140-6736(07)60601-1. - DOI - PubMed
    1. Luciano R.L., Dahl N.K. Extra-renal manifestations of autosomal dominant polycystic kidney disease (ADPKD): considerations for routine screening and management. Nephrol Dial Transplant. 2014;29:247–254. doi: 10.1093/ndt/gft437. - DOI - PubMed
    1. Yang H., Sieben C.J., Schauer R.S., Harris P.C. Genetic spectrum of polycystic kidney and liver diseases and the resulting phenotypes. Adv Kidney Dis Health. 2023;30:397–406. doi: 10.1053/j.akdh.2023.04.004. - DOI - PMC - PubMed
    1. Porath B., Gainullin V.G., Cornec-Le Gall E., et al. Mutations in GANAB, encoding the glucosidase IIα subunit, cause autosomal-dominant polycystic kidney and liver disease. Am J Hum Genet. 2016;98:1193–1207. doi: 10.1016/j.ajhg.2016.05.004. - DOI - PMC - PubMed
    1. Perrone R.D., Malek A.M., Watnick T. Vascular complications in autosomal dominant polycystic kidney disease. Nat Rev Nephrol. 2015;11:589–598. doi: 10.1038/nrneph.2015.128. - DOI - PMC - PubMed